Search Results
10
Everything
Search Filters
Organization
Verve Therapeutics
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
March 24, 2025 07:00 ET
|
Verve Therapeutics
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 03, 2025 16:05 ET
|
Verve Therapeutics
BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on February 28,...
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025 07:00 ET
|
Verve Therapeutics
Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose escalation data in the second half of 2025 VERVE-102...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 03, 2025 16:05 ET
|
Verve Therapeutics
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31,...
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025 07:00 ET
|
Verve Therapeutics
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan,...
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones
January 13, 2025 07:00 ET
|
Verve Therapeutics
Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301...
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025 07:00 ET
|
Verve Therapeutics
BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan,...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 03, 2025 16:05 ET
|
Verve Therapeutics
BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31,...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 29, 2024 16:05 ET
|
Verve Therapeutics
BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,...
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
November 05, 2024 07:00 ET
|
Verve Therapeutics
Seven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025 First participant dosed in the Pulse-1...